SCHEMBL544290

SCHEMBL544290

COC(=O)c1cnc(Br)c(-c2ccc(Cl)c(OCc3ccccc3)c2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.53
CNR1 P21554 1/20 0.44
MGAM O43451 1/20 0.43
GAA P10253 1/20 0.43
SI P14410 1/20 0.43
MGAM2 Q2M2H8 1/20 0.43
MRGPRX4 Q96LA9 2/20 0.42
CTSA P10619 1/20 0.41
PTGER1 P34995 2/20 0.41
MCL1 Q07820 1/20 0.41
EGFR P00533 1/20 0.40
ERBB2 P04626 1/20 0.40
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HPGD P15428 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4041265 0.90 PTGER1 (0.46) NOTUMMGAMGAASIMGAM2
SCHEMBL545186 0.88 NOTUM (0.53) NOTUMCNR1MGAMGAASI
SCHEMBL544276 0.85 NOTUM (0.50) NOTUMCNR1MGAMGAASI
SCHEMBL544534 0.85 NOTUM (0.56) NOTUMCNR1MGAMGAASI
SCHEMBL28782031 0.82 NOTUM (0.48) NOTUMCNR1MGAMGAASI
SCHEMBL544928 0.81 NOTUM (0.52) NOTUMCNR1MGAMGAASI
SCHEMBL544317 0.80 CNR1 (0.49) NOTUMCNR1MGAMGAASI
SCHEMBL544584 0.80 NOTUM (0.51) NOTUMCNR1MGAMGAASI
SCHEMBL544620 0.79 NOTUM (0.50) NOTUMCNR1MGAMGAASI
SCHEMBL544265 0.79 NOTUM (0.50) NOTUMCNR1MGAMGAASI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8552201-B2 5, 6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin II receptor antagonists SANOFI (FR) 2013-10-08 US disclosed
CN-101511789-B 5, 6-bisaryl-2-pyridine-carboxamide derivatives, their preparation and their use in therapy as urotensin II receptor antagonists SANOFI AVENTIS 2012-05-23 CN disclosed
US-20120108611-A1 5, 6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS SANOFI-AVENTIS 2012-05-03 US disclosed
US-8110579-B2 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin II receptor antagonists SANOFI-AVENTIS (FR) 2012-02-07 US disclosed
US-20090318473-A1 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS SANOFI AVENTIS 2009-12-24 US disclosed
CN-101511789-A 5, 6-bisaryl-2-pyridine-carboxamide derivatives, their preparation and their use in therapy as urotensin II receptor antagonists SANOFI AVENTIS (FR) 2009-08-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318473-A1 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS UTS2R, PLAUR, NTSR2 NOTUM 3247/4885CNR1 51/4885MGAM 2110/4885
US-20120108611-A1 5, 6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS UTS2R, PLAUR, NTSR2 NOTUM 3247/4885CNR1 51/4885MGAM 2110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.